Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) Director Ellen Strahlman acquired 12,112 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was purchased at an average price of $3.60 per share, with a total value of $43,603.20. Following the completion of the acquisition, the director directly owned 91,161 shares in the company, valued at approximately $328,179.60. This represents a 15.32% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Hyperion DeFi Price Performance
Shares of NASDAQ HYPD traded down $0.13 during trading hours on Tuesday, reaching $3.37. 193,370 shares of the stock traded hands, compared to its average volume of 1,525,525. The company’s 50-day simple moving average is $4.87 and its two-hundred day simple moving average is $7.60. The company has a market capitalization of $27.53 million, a P/E ratio of -0.83 and a beta of 2.81. Hyperion DeFi, Inc. has a 52-week low of $0.85 and a 52-week high of $17.99. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11.
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last issued its earnings results on Friday, November 14th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $0.36 million during the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%. Equities research analysts forecast that Hyperion DeFi, Inc. will post -41.6 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Hyperion DeFi
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
See Also
- Five stocks we like better than Hyperion DeFi
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Bombshell Exposé on China Strikes
- Wall Street Stockpicker Names #1 Stock of 2026
- [URGENT!] SpaceX Going Public! – Pre-IPO Action
- End of America update
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
